vs

Side-by-side financial comparison of NCS Multistage Holdings, Inc. (NCSM) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $50.6M, roughly 1.4× NCS Multistage Holdings, Inc.). NCS Multistage Holdings, Inc. runs the higher net margin — 29.5% vs -49.0%, a 78.6% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 12.5%). NCS Multistage Holdings, Inc. produced more free cash flow last quarter ($12.9M vs $-84.7M).

NCS Multistage Holdings, Inc. is a global oilfield services and energy technology provider specializing in engineered completion systems for onshore and offshore oil and gas production. It offers multistage fracturing tools that optimize well performance, serving major operators across North America, Latin America, the Middle East and Asia-Pacific, focusing on boosting operational efficiency and resource recovery for upstream energy clients.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

NCSM vs VRDN — Head-to-Head

Bigger by revenue
VRDN
VRDN
1.4× larger
VRDN
$70.6M
$50.6M
NCSM
Growing faster (revenue YoY)
VRDN
VRDN
+81945.6% gap
VRDN
81958.1%
12.5%
NCSM
Higher net margin
NCSM
NCSM
78.6% more per $
NCSM
29.5%
-49.0%
VRDN
More free cash flow
NCSM
NCSM
$97.6M more FCF
NCSM
$12.9M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
NCSM
NCSM
VRDN
VRDN
Revenue
$50.6M
$70.6M
Net Profit
$15.0M
$-34.6M
Gross Margin
Operating Margin
10.3%
-56.7%
Net Margin
29.5%
-49.0%
Revenue YoY
12.5%
81958.1%
Net Profit YoY
331.0%
54.9%
EPS (diluted)
$5.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NCSM
NCSM
VRDN
VRDN
Q4 25
$50.6M
Q3 25
$46.5M
$70.6M
Q2 25
$36.5M
Q1 25
$50.0M
Q4 24
$45.0M
Q3 24
$44.0M
Q2 24
$29.7M
Q1 24
$43.9M
Net Profit
NCSM
NCSM
VRDN
VRDN
Q4 25
$15.0M
Q3 25
$3.8M
$-34.6M
Q2 25
$924.0K
Q1 25
$4.1M
Q4 24
$3.5M
Q3 24
$4.1M
Q2 24
$-3.1M
Q1 24
$2.1M
Operating Margin
NCSM
NCSM
VRDN
VRDN
Q4 25
10.3%
Q3 25
6.6%
-56.7%
Q2 25
-5.6%
Q1 25
8.6%
Q4 24
6.5%
Q3 24
6.9%
Q2 24
-14.0%
Q1 24
5.7%
Net Margin
NCSM
NCSM
VRDN
VRDN
Q4 25
29.5%
Q3 25
8.2%
-49.0%
Q2 25
2.5%
Q1 25
8.1%
Q4 24
7.7%
Q3 24
9.4%
Q2 24
-10.4%
Q1 24
4.7%
EPS (diluted)
NCSM
NCSM
VRDN
VRDN
Q4 25
$5.43
Q3 25
$1.37
Q2 25
$0.34
Q1 25
$1.51
Q4 24
$1.34
Q3 24
$1.60
Q2 24
$-1.21
Q1 24
$0.82

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NCSM
NCSM
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$36.7M
$490.9M
Total DebtLower is stronger
$5.3M
Stockholders' EquityBook value
$126.2M
$503.0M
Total Assets
$181.2M
$577.1M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NCSM
NCSM
VRDN
VRDN
Q4 25
$36.7M
Q3 25
$25.3M
$490.9M
Q2 25
$25.4M
Q1 25
$23.0M
Q4 24
$25.9M
Q3 24
$15.3M
Q2 24
$18.6M
Q1 24
$14.0M
Total Debt
NCSM
NCSM
VRDN
VRDN
Q4 25
$5.3M
Q3 25
$5.1M
Q2 25
$5.5M
Q1 25
$5.4M
Q4 24
$6.0M
Q3 24
$6.5M
Q2 24
$6.8M
Q1 24
$6.4M
Stockholders' Equity
NCSM
NCSM
VRDN
VRDN
Q4 25
$126.2M
Q3 25
$110.1M
$503.0M
Q2 25
$106.4M
Q1 25
$103.2M
Q4 24
$98.8M
Q3 24
$96.0M
Q2 24
$91.0M
Q1 24
$93.7M
Total Assets
NCSM
NCSM
VRDN
VRDN
Q4 25
$181.2M
Q3 25
$162.0M
$577.1M
Q2 25
$158.0M
Q1 25
$155.1M
Q4 24
$152.8M
Q3 24
$145.8M
Q2 24
$139.4M
Q1 24
$140.9M
Debt / Equity
NCSM
NCSM
VRDN
VRDN
Q4 25
0.04×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.06×
Q3 24
0.07×
Q2 24
0.08×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NCSM
NCSM
VRDN
VRDN
Operating Cash FlowLast quarter
$13.1M
$-84.6M
Free Cash FlowOCF − Capex
$12.9M
$-84.7M
FCF MarginFCF / Revenue
25.5%
-120.1%
Capex IntensityCapex / Revenue
0.4%
0.2%
Cash ConversionOCF / Net Profit
0.88×
TTM Free Cash FlowTrailing 4 quarters
$21.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NCSM
NCSM
VRDN
VRDN
Q4 25
$13.1M
Q3 25
$7.2M
$-84.6M
Q2 25
$3.5M
Q1 25
$-1.6M
Q4 24
$10.6M
Q3 24
$-2.0M
Q2 24
$6.0M
Q1 24
$-1.9M
Free Cash Flow
NCSM
NCSM
VRDN
VRDN
Q4 25
$12.9M
Q3 25
$6.9M
$-84.7M
Q2 25
$3.2M
Q1 25
$-2.1M
Q4 24
$10.4M
Q3 24
$-2.5M
Q2 24
$5.6M
Q1 24
$-2.2M
FCF Margin
NCSM
NCSM
VRDN
VRDN
Q4 25
25.5%
Q3 25
14.9%
-120.1%
Q2 25
8.9%
Q1 25
-4.2%
Q4 24
23.1%
Q3 24
-5.6%
Q2 24
19.0%
Q1 24
-5.0%
Capex Intensity
NCSM
NCSM
VRDN
VRDN
Q4 25
0.4%
Q3 25
0.5%
0.2%
Q2 25
0.8%
Q1 25
0.9%
Q4 24
0.5%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
0.7%
Cash Conversion
NCSM
NCSM
VRDN
VRDN
Q4 25
0.88×
Q3 25
1.88×
Q2 25
3.81×
Q1 25
-0.41×
Q4 24
3.07×
Q3 24
-0.49×
Q2 24
Q1 24
-0.91×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NCSM
NCSM

Products$33.8M67%
Services$16.8M33%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons